Progressive giant cell myocarditis presenting with inappropriate shocks from a subcutaneous defibrillator.
作者信息
Phan Justin, Subbiah Rajesh, Walker Bruce, Lee William
机构信息
St Vincent's Hospital, Darlinghurst, Australia.
University of New South Wales, Sydney, Australia.
出版信息
HeartRhythm Case Rep. 2022 Mar 10;8(5):378-382. doi: 10.1016/j.hrcr.2022.03.002. eCollection 2022 May.
Abstract
摘要
相似文献
1
Progressive giant cell myocarditis presenting with inappropriate shocks from a subcutaneous defibrillator.
HeartRhythm Case Rep. 2022 Mar 10;8(5):378-382. doi: 10.1016/j.hrcr.2022.03.002. eCollection 2022 May.
2
Subcutaneous Implantable Cardioverter Defibrillator Lead Repositioning for Preventing Inappropriate Shocks Due to Myopotential Oversensing in a Post-Fulminant Myocarditis Patient.
Int Heart J. 2019 Mar 20;60(2):466-469. doi: 10.1536/ihj.18-324. Epub 2019 Feb 8.
3
Incidence, mechanisms, and clinical impact of inappropriate shocks in patients with a subcutaneous defibrillator.
Europace. 2020 May 1;22(5):761-768. doi: 10.1093/europace/euaa026.
4
Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management.
Int J Cardiol. 2015 Sep 15;195:126-33. doi: 10.1016/j.ijcard.2015.05.135. Epub 2015 May 22.
5
Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator.
Heart Rhythm. 2018 Oct;15(10):1515-1522. doi: 10.1016/j.hrthm.2018.05.011. Epub 2018 Jun 8.
6
Association of Night-Time Heart Rate With Ventricular Tachyarrhythmias, Appropriate and Inappropriate Implantable Cardioverter-Defibrillator Shocks.
Front Cardiovasc Med. 2021 Sep 6;8:739889. doi: 10.3389/fcvm.2021.739889. eCollection 2021.
7
Usefulness of subcutaneous implantable cardioverter-defibrillator therapy in patients with Brugada syndrome.
Heart Vessels. 2021 Feb;36(2):260-266. doi: 10.1007/s00380-020-01683-0. Epub 2020 Aug 24.
8
Inappropriate shocks by subcutaneous implantable cardioverter-defibrillator due to T-wave oversensing in hyperkalemia leading to ventricular fibrillation.
HeartRhythm Case Rep. 2015 May 7;1(4):257-259. doi: 10.1016/j.hrcr.2015.04.007. eCollection 2015 Jul.
9
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
J Am Coll Cardiol. 2008 Apr 8;51(14):1357-65. doi: 10.1016/j.jacc.2007.09.073.
10
Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator.
Heart Rhythm. 2014 Aug;11(8):1352-8. doi: 10.1016/j.hrthm.2014.04.012. Epub 2014 Apr 13.
本文引用的文献
1
A Shocking Case of Far-Field Atrial Oversensing in Giant-Cell Myocarditis.
JACC Case Rep. 2021 Apr 21;3(4):603-609. doi: 10.1016/j.jaccas.2021.02.041. eCollection 2021 Apr.
2
Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week.
J Am Coll Cardiol. 2021 Mar 2;77(8):1122-1134. doi: 10.1016/j.jacc.2020.11.074.
3
Usefulness of lead repositioning to improve subcutaneous electrocardiogram sensing in patients with arrhythmogenic right ventricular cardiomyopathy with subcutaneous implantable cardioverter-defibrillator.
HeartRhythm Case Rep. 2020 Aug 4;6(10):786-790. doi: 10.1016/j.hrcr.2020.07.023. eCollection 2020 Oct.
4
Subcutaneous or Transvenous Defibrillator Therapy.
N Engl J Med. 2020 Aug 6;383(6):526-536. doi: 10.1056/NEJMoa1915932.
5
Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator.
Heart Rhythm. 2018 Oct;15(10):1515-1522. doi: 10.1016/j.hrthm.2018.05.011. Epub 2018 Jun 8.
6
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
Circulation. 2018 Sep 25;138(13):e210-e271. doi: 10.1161/CIR.0000000000000548.
7
Incidence, Risk Factors, and Outcome of Life-Threatening Ventricular Arrhythmias in Giant Cell Myocarditis.
Circ Arrhythm Electrophysiol. 2016 Dec;9(12). doi: 10.1161/CIRCEP.116.004559.
8
ICD Shock, Not Ventricular Fibrillation, Causes Elevation of High Sensitive Troponin T after Defibrillation Threshold Testing--The Prospective, Randomized, Multicentre TropShock-Trial.
PLoS One. 2015 Jul 24;10(7):e0131570. doi: 10.1371/journal.pone.0131570. eCollection 2015.
9
Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.
J Am Coll Cardiol. 2015 Apr 28;65(16):1605-1615. doi: 10.1016/j.jacc.2015.02.047.
10
Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators.
N Engl J Med. 1997 Jun 26;336(26):1860-6. doi: 10.1056/NEJM199706263362603.
Zotero 插件